IPSEN – Buy-back programme – Art 5 of MAR – Week 32 – 2023
Aggregated presentation by day and by market
Name of issuer | Identification code of issuer (Legal Entity Identifier) | Day of transaction | Identification code of financial instrument | Aggregated daily volume (in number of shares) | Daily weighted average price of the purchased shares * | Market (MIC Code) |
IPSEN | 549300M6SGDPB4Z94P11 | 07/08/2023 | FR0010259150 | 40 | 115.70 | CEUX |
IPSEN | 549300M6SGDPB4Z94P11 | 07/08/2023 | FR0010259150 | 1,560 | 115.33 | XPAR |
IPSEN | 549300M6SGDPB4Z94P11 | 08/08/2023 | FR0010259150 | 61 | 121.00 | AQEU |
IPSEN | 549300M6SGDPB4Z94P11 | 08/08/2023 | FR0010259150 | 34 | 118.30 | CEUX |
IPSEN | 549300M6SGDPB4Z94P11 | 08/08/2023 | FR0010259150 | 1,505 | 119.50 | XPAR |
IPSEN | 549300M6SGDPB4Z94P11 | 09/08/2023 | FR0010259150 | 47 | 120.70 | AQEU |
IPSEN | 549300M6SGDPB4Z94P11 | 09/08/2023 | FR0010259150 | 158 | 120.85 | TQEX |
IPSEN | 549300M6SGDPB4Z94P11 | 09/08/2023 | FR0010259150 | 1,395 | 120.75 | XPAR |
IPSEN | 549300M6SGDPB4Z94P11 | 10/08/2023 | FR0010259150 | 2 | 122.10 | AQEU |
IPSEN | 549300M6SGDPB4Z94P11 | 10/08/2023 | FR0010259150 | 62 | 121.96 | CEUX |
IPSEN | 549300M6SGDPB4Z94P11 | 10/08/2023 | FR0010259150 | 1,536 | 121.76 | XPAR |
IPSEN | 549300M6SGDPB4Z94P11 | 11/08/2023 | FR0010259150 | 1,600 | 121.32 | XPAR |
* Two-digit rounding after the decimal | TOTAL | 8,000 | 119.74 |
Attachment
IPSEN – Buy-back programme – Art 5 of MAR – Week 32 – 2023
- 16 August 2023 - 1 mins read
Aggregated presentation by day and by market
Name of issuer | Identification code of issuer (Legal Entity Identifier) | Day of transaction | Identification code of financial instrument | Aggregated daily volume (in number of shares) | Daily weighted average price of the purchased shares * | Market (MIC Code) |
IPSEN | 549300M6SGDPB4Z94P11 | 07/08/2023 | FR0010259150 | 40 | 115.70 | CEUX |
IPSEN | 549300M6SGDPB4Z94P11 | 07/08/2023 | FR0010259150 | 1,560 | 115.33 | XPAR |
IPSEN | 549300M6SGDPB4Z94P11 | 08/08/2023 | FR0010259150 | 61 | 121.00 | AQEU |
IPSEN | 549300M6SGDPB4Z94P11 | 08/08/2023 | FR0010259150 | 34 | 118.30 | CEUX |
IPSEN | 549300M6SGDPB4Z94P11 | 08/08/2023 | FR0010259150 | 1,505 | 119.50 | XPAR |
IPSEN | 549300M6SGDPB4Z94P11 | 09/08/2023 | FR0010259150 | 47 | 120.70 | AQEU |
IPSEN | 549300M6SGDPB4Z94P11 | 09/08/2023 | FR0010259150 | 158 | 120.85 | TQEX |
IPSEN | 549300M6SGDPB4Z94P11 | 09/08/2023 | FR0010259150 | 1,395 | 120.75 | XPAR |
IPSEN | 549300M6SGDPB4Z94P11 | 10/08/2023 | FR0010259150 | 2 | 122.10 | AQEU |
IPSEN | 549300M6SGDPB4Z94P11 | 10/08/2023 | FR0010259150 | 62 | 121.96 | CEUX |
IPSEN | 549300M6SGDPB4Z94P11 | 10/08/2023 | FR0010259150 | 1,536 | 121.76 | XPAR |
IPSEN | 549300M6SGDPB4Z94P11 | 11/08/2023 | FR0010259150 | 1,600 | 121.32 | XPAR |
* Two-digit rounding after the decimal | TOTAL | 8,000 | 119.74 |
Attachment
Related Press Releases
09 December 2024
1 mins read
Ipsen – November 2024 – Monthly information relative to the total number of voting rights and shares composing the share capital
07 November 2024
1 mins read
Ipsen – October 2024 – Monthly information relative to the total number of voting rights and shares composing the share capital
09 October 2024
1 mins read
Ipsen – September 2024 – Monthly information relative to the total number of voting rights and shares composing the share capital
18 September 2024
9 mins read
Final results from CABINET Phase III trial reinforce efficacy benefits of Cabometyx® in advanced neuroendocrine tumors
16 September 2024
9 mins read
Final results from CABINET Phase III trial reinforce efficacy benefits of Cabometyx® in advanced neuroendocrine tumors
15 September 2024
7 mins read
Ipsen provides update on CONTACT-02 Phase III trial in metastatic castration-resistant prostate cancer following final overall survival analysis
04 September 2024
1 mins read
Ipsen – August 2024 – Monthly information relative to the total number of voting rights and shares composing the share capital
30 August 2024
1 mins read
Testing video 1
30 August 2024
1 mins read
Testing video 3
30 August 2024
1 mins read